Previous Close | 1.4800 |
Open | 1.4700 |
Bid | 1.4300 x 800 |
Ask | 1.5800 x 1400 |
Day's Range | 1.4700 - 1.5050 |
52 Week Range | 1.1300 - 3.6200 |
Volume | 573,706 |
Avg. Volume | 150,442 |
Market Cap | 74M |
Beta (5Y Monthly) | 0.97 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4770 |
Earnings Date | Nov 8, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.75 |
Q3 2019 Neos Therapeutics Inc Earnings Call
DALLAS and FORT WORTH, Texas, Nov. 08, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery.
DALLAS and FORT WORTH, Texas, Nov. 01, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery.
If you're interested in Neos Therapeutics, Inc. (NASDAQ:NEOS), then you might want to consider its beta (a measure of...
DALLAS and FORT WORTH, Texas, Sept. 25, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery.
DALLAS and FORT WORTH, Texas, Aug. 29, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery.
Q2 2019 Neos Therapeutics Inc Earnings Call
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 50.00% and -6.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
– Company to host conference call today at 8:30am EDT – DALLAS and FORT WORTH, Texas, Aug. 08, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage.
DALLAS and FORT WORTH, Texas, Aug. 01, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.
DALLAS and FORT WORTH, Texas, June 12, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
DALLAS and FORT WORTH, Texas, May 30, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
Neos Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Q1 2019 Neos Therapeutics Inc Earnings Call
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 31.82% and 3.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Grand Prairie, Texas-based company said it had a loss of 15 cents per share. The pharmaceutical company posted revenue of $14.6 million in the period. The company's shares closed at $2.08. A year ago, ...
DALLAS and FORT WORTH, Texas, May 09, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
DALLAS and FORT WORTH, Texas, May 02, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
Neos Therapeutics (NEOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Neos Therapeutics (NEOS) stock based on the movements in the options market lately.
Q4 2018 Neos Therapeutics Inc Earnings Call
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies. Warning! GuruFocus has detected 1 Warning Sign with NEOS. For the last quarter Neos Therapeutics Inc reported a revenue of $15.4 million, compared with the revenue of $7.11 million during the same period a year ago.